InsiderTrades

Form 4/A for SMMT Summit Therapeutics Inc.

Accepted 2023-03-13 00:00:00 ET · period of report 2023-03-08 · accession 0001387131-23-003381 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MAI 2023-03-13 2023-03-08 SMMT Zanganeh Mahkam Pres, Co-CEO, Dir P - Purchase $1.05 +23.53M 9.88M New +$24.70M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-08 P A 16,778,415 $1.05 24,573,798 I By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. — — (F2) Includes the number of shares of Common Stock that were inadvertently previously disclosed as being held by Dr. Zanganeh personally, which are held by the Mahkam Zanganeh Revocable Trust. Dr. Zanganeh does not directly hold any shares personally, all of her shares are held through the Mahkam Zanganeh Revocable Trust. (F1) Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. (F3) The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
2 Common Common Stock 2023-03-08 P A 6,748,629 $1.05 9,884,095 I By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee. — — (F1) Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. (F3) The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.